<DOC>
	<DOCNO>NCT00002317</DOCNO>
	<brief_summary>To evaluate safety efficacy trimetrexate glucuronate leucovorin protection pediatric patient Pneumocystis carinii pneumonia ( PCP ) refractory demonstrate severe life-threatening toxicity standard therapy ( e.g. , TMP/SMX parenteral pentamidine ) .</brief_summary>
	<brief_title>A Study Trimetrexate Plus Leucovorin Children With Pneumocystis Carinii Pneumonia</brief_title>
	<detailed_description>Patients receive intravenous infusion trimetrexate glucuronate leucovorin 21 day . Leucovorin continue 3 additional day discontinuation trimetrexate glucuronate . Patients follow 1 month .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Trimetrexate</mesh_term>
	<criteria>Inclusion Criteria Patients must : Pneumocystis carinii pneumonia ( PCP ) confirm within 15 day prior study entry . Serious intolerance and/or resistance standard therapy ( trimethoprim/sulfamethoxazole parenteral pentamidine ) course therapy current episode PCP , OR document history intolerance prior episode . Exclusion Criteria Patients follow prior condition exclude : History Type I hypersensitivity ( i.e. , urticaria , angioedema , anaphylaxis ) , exfoliative dermatitis , lifethreatening reaction due trimetrexate glucuronate .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>July 1993</verification_date>
	<keyword>Trimetrexate</keyword>
	<keyword>Pneumonia , Pneumocystis carinii</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>